LTIP y esquema de opciones sobre acciones
Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan
Hong Kong, Shanghai y Florham Park, Nueva Jersey: jueves14 de marzo de 2024: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM; HKEX: 13) announces that on March 14, 2024, it granted share options ("Share Options") under the Share Option Scheme adopted by HUTCHMED in 2015 (the "Share Option Scheme") and awards ("LTIP Awards") under the Long Term Incentive Plan adopted by HUTCHMED in 2015 ("LTIP").
Aimed at attracting and retaining top talent, the Remuneration Committee of HUTCHMED appointed an independent advisor to conduct compensation benchmarking research on a selected peer group of companies. As a result of this the Remuneration Committee has comprehensively reviewed the compensation and share-based incentives policies of HUTCHMED and its subsidiaries (the "Group") and established an attractive policy to ensure the Group is able to recruit and retain top talent. In line with this review HUTCHMED has decided to make the following grant of Share Options and LTIP Awards.
1. Performance Related Share Options
HUTCHMED granted Share Options subject to the Performance Targets (defined below) under its Share Option Scheme to Dr Weiguo Su (Executive Director, Chief Executive Officer and Chief Scientific Officer), being a person discharging managerial responsibility ("PDMR") under the UK Market Abuse Regulation to subscribe for a total of 1,359,561 ordinary shares with par value US$0.10 each in the share capital of the Company ("Ordinary Shares") subject to the acceptance of the grantee. Details of such Share Options granted are as follows:
Fecha de concesión | : | Marzo 13, 2024
|
Precio de ejercicio de las opciones sobre acciones concedidas | : | HK$28.35 per Ordinary Share
|
Número de opciones sobre acciones concedidas | : | 1,359,561 acciones ordinarias
|
Precio de mercado de cierre de las acciones ordinarias en HKEX en la fecha de concesión
| : | HK$28.35 per Ordinary Share
|
Período de ejercicio de las opciones sobre acciones | : | Del 13 de marzo de 2024 al 12 de marzo de 2034
|
Período de consolidación de las opciones sobre acciones | : | Vesting will occur two business days after the date of announcement of the annual results of the Company for the financial year ending December 31, 2025 (the "2025 Results Announcement").
|
Objetivos de rendimiento | : | The exercise of the share options is conditional upon the fulfilment of certain performance targets relating to the Group over the financial years 2023 to 2025 (the "Performance Targets"). The number of share options to be exercisable will be determined on the date of 2025 Results Announcement. The Performance Targets have been determined by the Board and specified in the grant letter of Dr Su. To the extent that the Performance Targets have not been met, the relevant number of share options granted to Dr Su will lapse.
|
mecanismo de recuperación | : | The share options may be subject to the clawback policy of the Company enabling the Company to recover incentive-based compensation paid to covered executive officers in the event of mis-statement of the financial statements of the Company resulting from material non-compliance with financial reporting requirements. |
After the above grant of Share Options, the number of Share Options available for future grant under the scheme mandate of the Share Option Scheme is 11,678,982.
2. Non-performance-related LTIP Award ("Non-performance LTIP Award") - a one-off cash amount was granted to each grantee and will be used by the trustee administering the LTIP (the "Trustee") to purchase Ordinary Shares in HUTCHMED which will be subject to a vesting schedule over four years. HUTCHMED granted the following Non-performance LTIP Awards to the following Executive Director, being a PDMR under the UK Market Abuse Regulation:
Titular del premio |
| Cash amount for the Non- Premios LTIP de rendimiento |
|
|
|
Dr. Weiguo Su (director ejecutivo, director ejecutivo y director científico) |
| US$500,000 |
The non-performance-related LTIP Award was granted to Dr Su in recognition of his contribution to the Company in his dual role as Chief Executive Officer and Chief Scientific Officer.
Another employee of the Group has simultaneously been granted non-performance related LTIP Awards.
The notification in respect of share options granted to Dr Su in accordance with the requirements of the UK Market Abuse Regulation is set out below.
Dr. Weiguo Su
1 | Detalles de la persona que cumple con las responsabilidades de gestión / persona estrechamente asociada | |||||||
a) |
Nombre |
Dr. Weiguo Su
| ||||||
2 | Razón de la notificación | |||||||
a) |
Posición / estado |
Executive Director, Chief Executive Officer and Chief Scientific Officer
| ||||||
b) |
Notificación inicial / Enmienda
|
Notificación inicial
| ||||||
3 | Datos del emisor, participante en el mercado de derechos de emisión, plataforma de subastas, subastador o supervisor de subastas | |||||||
a) |
Nombre
|
HUTCHMED (China) limitada | ||||||
b)
|
LEY |
2138006X34YDQ6OBYE79 | ||||||
4 | Detalles de la (s) transacción (es): sección que se repetirá para (i) cada tipo de instrumento; (ii) cada tipo de transacción; (iii) cada fecha; y (iv) cada lugar donde se han realizado transacciones | |||||||
a) |
Descripción del instrumento financiero, tipo de instrumento
Código de identificación |
Share option over Ordinary Shares of US$0.10
Share option over Ordinary Share with DI ISIN: KYG4672N1016 | ||||||
b) |
Naturaleza de la transacción
|
Grant of options in respect of 1,359,561 Ordinary Shares under the Share Option Scheme.
The exercise of the share options is conditional upon the fulfilment of certain performance targets relating to the Group over the financial years 2023 to 2025 (the "Performance Targets"). The number of share options to be exercisable will be determined on the date of 2025 Results Announcement. The Performance Targets have been determined by the Board and specified in the grant letter of Dr Su. To the extent that the Performance Targets have not been met, the relevant number of share options granted to Dr Su will lapse.
| ||||||
c) |
Precio (s) y volumen (es) |
| ||||||
d) |
Información agregada
|
N/A | ||||||
e) |
Fecha de la transacción |
2024-3-13
| ||||||
f) |
Lugar de la transacción |
Fuera de un centro de negociación
|
Sobre HUTCHMED
HUTCHMED (Nasdaq/AIM:?HCM; HKEX:?13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/?immunology. Since inception, it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also marketed in the U.S.. For more information, please visit: www.hutch?med.com or follow us on LinkedIn.
adelante-Mirando Declaraciones
Este anuncio contiene declaraciones a futuro dentro del significado de las disposiciones de "puerto seguro" de la Ley de Reforma de Litigios de Valores Privados de EE. UU. de 1995. Las declaraciones a futuro implican riesgos e incertidumbres. Se advierte a los inversores actuales y potenciales que no depositen una confianza indebida en estas declaraciones prospectivas, que se refieren únicamente a la fecha del presente. Para obtener más información sobre estos y otros riesgos, consulte las presentaciones de HUTCHMED ante la Comisión de Bolsa y Valores de EE. UU., sobre AIM y sobre HKEX. HUTCHMED no asume ninguna obligación de actualizar o revisar la información contenida en este anuncio, ya sea como resultado de nueva información, eventos o circunstancias futuras o de otra manera.
CONTACTO
Consultas de inversores | +852 2121 8200 / GME@dhr-rgv.com |
Preguntas de los medios |
|
Ben Atwell/Alex Shaw, Consultoría FTI | +44 20 3727 1030 / + 44 7771 913 902 (Móvil) / +44 7779 545 055 (Móvil) | GME@dhr-rgv.com |
Zhou Yi, Brunswick | +852 9783 6894 (Móvil) |
Asesor Nominado | |
Atholl Tweedie / Freddy Crossley / Daphne Zhang, Panmure Gordon | +44 (20) 7886 2500 |
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.